

The Fetal medicine Foundation is grateful to the following sponsors and exhibitors for supporting the 10th World Congress in Fetal Medicine

Platinum Level Sponsor



SAMSUNG MEDISON

lightest and most portable of scanners, to the very latest and most sophisticated in ultrasound technology. Samsung Medison also produces digital X-rays and other medical imaging products. For more information, please visit www.samsungmedison.com

Samsung Medison is one of the world's leading researchers, developers and manufacturers of ultrasound and other medical imaging products. Founded in 1985, Samsung Medison was acquired by Samsung Electronics in February 2011. Throughout its history, the company has achieved a series of technological breakthroughs, such as introducing the world's first commercially available 3D and 4D diagnostic ultrasound scanners. Driven by an investment of 12 percent of revenues into R&D, its range of machines now covers everything from the

Gold Level Sponsor



serum assays, PerkinElmer is pioneering the use of dried blood spot sampling (DBS) as a means of making screening more widely available. The new AutoDELFI[®]A/Free hCG β Dual DBS Kit provides the same screening performance as 1st trimester serum assays.

PerkinElmer is developing new methods for assessing the risk of other adverse pregnancy outcomes. DELFI[®]Xpress PIGF is the first placental growth factor (PIGF) assay designed for use as an aid in screening pregnant women for pre-eclampsia. The utility of maternal serum PIGF measurement in pre-eclampsia prediction has been confirmed in many studies. Pregnancies destined to develop pre-eclampsia are typically associated with a reduced level of the analyte already in the first trimester, making PIGF an ideal marker for early screening. It can be used together with maternal history and other marker information to identify those pregnancies at risk. PIGF is most sensitive and specific as a marker of the more severe early-onset form of pre-eclampsia.

Prenatal BoBs[™] is a bead-based multiplex assay designed to detect aneuploidies of chromosomes 13, 18, 21, X and Y, as well as copy number changes in 9 common microdeletion syndrome regions. Prenatal BoBs is a simple, robust assay that offers significant benefits in terms of ease of use, minute sample volumes, reduced time-to-result and improved pick-up rates for today's cytogenetics and molecular genetics laboratories.

Perkin Elmer is a global company focused on improving the health and safety of people and their environment. From earlier medical insights and more effective therapies to cleaner water and safer homes, PerkinElmer touches the lives of millions of people around the world every day. A leader in prenatal screening biochemistry assays, the company supplies a range of platforms together with the key analytes for 1st and 2nd trimester aneuploidy screening. The three main PerkinElmer platforms together with the assays for PAPP-A and free hCG β have received FMF approval for 1st trimester screening. As well as offering a wide selection of

Standard Plus Level Sponsors



Medicine Foundation (FMF), UK

The company's newest analytical instrument, KRYPTOR compact PLUS was certified by the FMF December 15th, 2010, meaning that KRYPTOR compact PLUS is fulfilling the requirements for first trimester biochemical screening.

B-R-A-H-M-S KRYPTOR, KRYPTOR compact and KRYPTOR compact PLUS platforms will use the same set of medians. Medians are established over a long period of time and their stability is important to maintain an effective screening program. Since it has been established - because all platforms use exactly the same reagent system - the medians on each machine are interchangeable and therefore any lab wishing to change to compact would not need to re-evaluate medians. This has never been possible with any other analytical platform before.

B-R-A-H-M-S GmbH, Part of Thermo Fisher, specializes in innovative products which facilitate earlier diagnosis of diseases and better control of therapy, thus enabling doctors to provide more efficient and economic patient care. Major fields of activity are laboratory tests in prenatal screening, thyroid diseases, oncology, sepsis, and cardiology.

The B-R-A-H-M-S analytical platform KRYPTOR is in routine use by the Fetal

GE Healthcare



GE Healthcare provides transformational medical technologies and services as well as professional consulting services that are shaping a new age of patient care. Our broad range of products, service and expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to better diagnose, inform, monitor and treat cancer, heart disease, neurological diseases and other conditions earlier.



improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80'000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

Roche, Headquartered in Basel, Switzerland, is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible



Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences was established in 1999 under the patronage of H.H. Sheikh Hamdan Bin Rashid Al Maktoum, Deputy Ruler of Dubai and Minister of Finance United Arab Emirates with the objective of honouring scientists from every part of the world who tirelessly pursue distinctive medical research that serves the larger interests of humanity.

The foundation is in the 7th term of awards and the subjects of the awards are selected carefully to reflect scientific advances made in the subject. The subject for the Grand Hamdan International Award for 2011-2012 is Neonatal Medicine. Hamdan Award for Medical Research Excellence is the second award in the International category and there are 3 subjects selected and are "Fetal Medicine, Nutrition in infants and inborn errors of Metabolism. As per the agenda of the awards, evaluation involves determining the factor that will be a research breakthrough in the subject selected for the award, having the potential to have a major impact on healthcare delivery. We expect a good number of excellent nominations from various parts of the world for the current term of 2011-2012. For more information and the details including rules & regulations and how to apply for this award please visit www.hmaward.org.ae

SIEMENS

Standard Level Sponsors

